Treatment Registry
TR-0524 ActiveRecorded September 2, 2026

Compounded semaglutide

Sold by EmbraceRX · Injection, vial · every compounded semaglutide record

What you actually pay

Per month

$117

Medication · Semaglutide + B12, entry-level dose, starting price$117

Added from the figures recorded below.

Price

TermPer monthCharged today
Semaglutide + B12, entry-level dose, starting price

Weight Loss Compounded GLP-1 · Semaglutide + B12 Starting from $117

source

Per month$117Charged today$117
Visit EmbraceRX

We earn nothing from this link. EmbraceRX has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.

History

One reading so far. A price history appears here after the next verification pass.

  • September 2, 2026Entry added to the register

Sourcing and terms

PrescriberAsynchronous review
Cancellation“You can always login to your account before your products ship to change your address, method of payment or to cancel your subscription.”

Not yet checked: pharmacy, states, membership and consult fee.

Recorded from embracerx.co. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2, 2026Each product's price is described as 'Starting from $X' with 'Price shown at checkout. Dose selection on the next step' — the exact per-dose price ladder beyond the starting figure is not published on these pages. The FAQ has a 'What states do we serve?' question with no rendered answer (accordion content not present in this tool's output), so states left not-found rather than guessed. Oral tirzepatide capsules are recorded under the enum's 'compounded tirzepatide' + form 'oral-tablet' since there is no distinct 'oral tirzepatide' enum value and no FDA-approved oral tirzepatide brand exists; the product page itself calls it 'Oral dual GIP/GLP-1 receptor agonist' with no brand name, consistent with a compounded oral formulation. Site prominently disclaims no association with Novo Nordisk/Eli Lilly brand products and states it does not supply Wegovy/Ozempic/Ozempic/Mounjaro/Saxenda.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0524
Readings
1

Related records

What else EmbraceRX sells

All EmbraceRX programs and terms

Compounded semaglutide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 298 records of the same molecule.

Cite this entry

Treatment Registry. (2026). EmbraceRX compounded semaglutide (TR-0524). Last verified September 2, 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0524

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.